Breaking News, Financial News

Financial Report: Ligand

Revenues double in the quarter

Ligand

1Q Revenues: $11.7 million (+107%)

1Q Earnings: $1.5 million (+32%)

Comments: Royalties were up 90% to $5.8 million driven by Promacta and new royalties from Kyprolis. Material sales were $1.5 million, up from $667,000 in 1Q12. Collaborative R&D revenues were $4.3 million, up from $1.9 million 1Q12.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters